Participated · Series A · May 2025

ReproNovo is a biopharmaceutical company focused on developing treatments for reproductive medicine and women’s health. Its lead clinical compound, RPN-001 (leflutrozole), is being developed to treat male infertility, while RPN-002 (nolasiban) is designed to manage adenomyosis and improve embryo implantation in ART. Both assets are Phase 2 ready. The company intends to use the Series A proceeds to advance a pipeline of multiple Phase 2 programs. ReproNovo is led by CEO Jean Marie Duvall, CSO & CMO Joan‑Carles Arce, MD, PhD, and CFO BingMei Hao. It maintains a primary development team in Copenhagen and an additional development site in Barcelona, with corporate base in Lausanne, Switzerland.

Participated · Series B · Sep 2024

Epsilogen's core product is MOv18 IgE, the first therapeutic IgE antibody to enter the clinic, which targets folate receptor alpha (FRα) expressed on multiple solid tumours. A completed Phase I trial showed MOv18 IgE to be safe and well tolerated with initial signs of clinical activity reported in Nature Communications. The company has completed large-scale GMP manufacture of MOv18 IgE and will initiate a Phase Ib two-part dose-escalation and expansion trial in FRα-positive platinum-resistant ovarian cancer later this year. Epsilogen is also developing a broader IgE-based pipeline, including IgE bispecifics and IgE/IgG combination molecules (IgEGs). The recent financing will fund delivery of clinical proof of concept for MOv18 IgE and further development across the IgE pipeline. Epsilogen develops novel immunoglobulin E (IgE) antibodies to treat cancer, with a focus on solid tumours. Its lead candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic. Data from a phase I trial showed MOv18 IgE to be safe and well tolerated with early signs of clinical activity. The company plans to establish clinical proof of concept for MOv18 IgE in a phase Ib trial in platinum-resistant ovarian cancer. Epsilogen is also advancing a proprietary IGEG antibody platform that combines elements of IgE and IgG to create molecules with enhanced functionality. The recent financing will fund the phase Ib study and continued development of the IGEG platform. Epsilogen began operations in 2017 as a King’s College London spin-out leveraging Professor Sophia Karagiannis’s IgE expertise.

Participated · Equity · Oct 2018

Smartvel is a Spanish startup that provides destination content solutions for the travel sector. Its technology leverages Big Data and Machine Learning to collect, classify, monitor, enrich, translate and geolocate events and static content from any destination worldwide. The product is integrated into clients' digital channels—airlines, tourist offices, hotel chains and travel agencies—to inspire travelers and help plan trips, improving customer experience and loyalty. Smartvel counts clients including Singapore Airlines, Iberia, the City of Buenos Aires, Iberostar Hotels, Nautalia, Mahou and Grupo Globalia. The company recently acquired UK content‑marketing firm Pearlshare. The $1.05M second funding round is intended to support international expansion and continued development of its technology and product.